Abstract
Background: Intramural hematoma (IMH) is a form of acute aortic syndrome. IMH is a life-threatening condition, with a mortality rate of 21% for type A and 5% for type B. Endovascular is a new minimally invasive method management aortic diseases with many benefits. Thoracic endovascular repair (TEVAR) to treat complicated or high-risk intramural hematoma with promising results.
Purposes: Evaluate the early results of the TEVAR management acute intramural hematoma.
Subjects and methods: This study prospectively analyzed 32 patients admitted Vietnam Heart Institute from January 2018 to the end of June 2021. They were diagnosed with acute type B intramural hematoma and underwent TEVAR . Evaluate the early results after TEVAR to treat acute type B IMH in 1-year follow-up.
Results: Incidence of IMH was higher in males, with 68.8% in man. Hypertension is the most common risk factors for IMH, was present in 84.4% patient with IMH. The technical success rate is 96,88%. The 30-day mortality rate was 0%. The 1-year follow-up mortality rate was 3.12% (caused by pneumonia). The most common complication after TEVAR was the post-implantation syndrome (65.6% in patient with IMH). Acute kidney injury accounted for 12.5%. In -hospital and during longitudinal follow-up stroke event was 3.12%. Results of aortic remodeling refer to increase the total aortic diameter (TAD), decrease in IMH thickness, decrease in ratio total aortic diameter/ true lumen diameter
Conclusion: TEVAR management in patients with acute type B intramural hematoma was safe technique with high success rate that promote remodeling of the aorta.